The Stakes Were High In This Phase II Study, But The Risk Was Under Control
Source: OmniComm Systems, Inc.
Challenges
- A midsize pharmaceutical company contracted a global CRO headquartered in Europe to conduct a global phase II study in infectious disease across 40 sites and 225 subjects.
- The molecules in clinical development were a breakthrough for the company and the stakes were high.
- Close monitoring of the scientific aspects as well as the operational performance of the study was essential.
- The client’s clinical team didn’t have processes or procedures to formally implement RBM.
- Limited additional budget.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
OmniComm Systems, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more